Pfizer Inc is close to an agreement to buy Medivation Inc for about US$14 billion, people familiar with the situation said, the latest in a long run of blockbuster deals in the drug and biotechnology industries.
The deal could be announced as early as Monday next week, said the people, who asked not to be identified because the matter is still private. The biotech company’s shares closed at US$67.16 on Friday, giving it a market value of US$11.1 billion.
By acquiring Medivation, Pfizer would gain a blockbuster prostate-cancer treatment, Xtandi, that is already approved for sale in the US and elsewhere and that analysts project will generate US$1.33 billion in annual sales by 2020.
Photo: Bloomberg
Pfizer chief executive officer Ian Read said in May that he was more interested in acquiring late-stage assets because the company already had plenty of early-stage drugs in the works.
Pfizer spokeswoman Joan Campion declined to comment.
Medivation representatives did not immediately respond to telephone calls and e-mails requesting comment.
Pfizer has been relying on new branded treatments, including cancer drugs, to boost revenue, as sales of older medicines have slowed. In August, the New York-based company reported earnings that beat expectations after sales of breast cancer treatment Ibrance were better than analysts’ estimates.
A US$14 billion purchase of Medivation would be Pfizer’s biggest deal since buying Hospira Inc for about US$17 billion last year and the company is a rare prize.
As oncology becomes one of the hottest areas in drug development, large drug and biotechnology firms have found only a few mid-sized targets with revenue-generating, approved treatments.
Though Xtandi is a blockbuster, Pfizer will split US sales with Tokyo-based Astellas Pharma Inc, which partnered with Medivation on the drug.
Medivation also comes with two experimental products: a drug for breast cancer and another for the blood cancer lymphoma. The breast cancer drug belongs to a class of treatments known as PARP inhibitors, which disrupt cancer cells’ process of DNA repair.
The drug, talazoparib, could well be the most potent medicine in the PARP class, according to Katherine Xu, an analyst at William Blair & Co in New York, who estimates annual peak sales could reach US$3 billion.
By spurning Sanofi’s initial offer, valued at about US$9 billion, Medivation was able to bring in more potential suitors and drive up the bidding.
Gilead Sciences Inc, Celgene Corp and Amgen Inc were among the other drugmakers reported to consider the deal.
Medivation previously rejected French drugmaker Sanofi’s offer of US$58 a share, plus a contingent value right valued at a maximum of US$3 a share. The Financial Times reported earlier on Sunday that the Pfizer agreement was imminent.
The deal is a blow to Sanofi’s cancer ambitions. It has spent five months both courting and pressuring Medivation to reach a takeover agreement.
Sanofi chief executive officer Olivier Brandicourt might have pushed his case too aggressively. After Sanofi’s initial offer of US$52.50 a share was spurned, the Paris-based drugmaker chose to go straight to Medivation investors, seeking their support to oust the board.
Medivation warned of a “devil’s bargain” that would usher in new directors who might settle for a takeover price that was not in shareholders’ interest. Sanofi dropped the hostility last month as Medivation agreed to enter into confidentiality agreements.
SEMICONDUCTORS: The firm has already completed one fab, which is to begin mass producing 2-nanomater chips next year, while two others are under construction Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), the world’s largest contract chipmaker, plans to begin construction of its fourth and fifth wafer fabs in Kaohsiung next year, targeting the development of high-end processes. The two facilities — P4 and P5 — are part of TSMC’s production expansion program, which aims to build five fabs in Kaohsiung. TSMC facility division vice president Arthur Chuang (莊子壽) on Thursday said that the five facilities are expected to create 8,000 jobs. To respond to the fast-changing global semiconductor industry and escalating international competition, TSMC said it has to keep growing by expanding its production footprints. The P4 and P5
DOWNFALL: The Singapore-based oil magnate Lim Oon Kuin was accused of hiding US$800 million in losses and leaving 20 banks with substantial liabilities Former tycoon Lim Oon Kuin (林恩強) has been declared bankrupt in Singapore, following the collapse of his oil trading empire. The name of the founder of Hin Leong Trading Pte Ltd (興隆貿易) and his children Lim Huey Ching (林慧清) and Lim Chee Meng (林志朋) were listed as having been issued a bankruptcy order on Dec. 19, the government gazette showed. The younger Lims were directors at the company. Leow Quek Shiong and Seah Roh Lin of BDO Advisory Pte Ltd are the trustees, according to the gazette. At its peak, Hin Leong traded a range of oil products, made lubricants and operated loading
The growing popularity of Chinese sport utility vehicles and pickup trucks has shaken up Mexico’s luxury car market, hitting sales of traditionally dominant brands such as Mercedes-Benz and BMW. Mexicans are increasingly switching from traditionally dominant sedans to Chinese vehicles due to a combination of comfort, technology and price, industry experts say. It is no small feat in a country home to factories of foreign brands such as Audi and BMW, and where until a few years ago imported Chinese cars were stigmatized, as in other parts of the world. The high-end segment of the market registered a sales drop
Citigroup Inc and Bank of America Corp said they are leaving a global climate-banking group, becoming the latest Wall Street lenders to exit the coalition in the past month. In a statement, Citigroup said while it remains committed to achieving net zero emissions, it is exiting the Net-Zero Banking Alliance (NZBA). Bank of America said separately on Tuesday that it is also leaving NZBA, adding that it would continue to work with clients on reducing greenhouse gas emissions. The banks’ departure from NZBA follows Goldman Sachs Group Inc and Wells Fargo & Co. The largest US financial institutions are under increasing pressure
RSS